ID   GLUC_RAT                Reviewed;         180 AA.
AC   P06883;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1988, sequence version 1.
DT   24-JUL-2024, entry version 164.
DE   RecName: Full=Pro-glucagon;
DE   Contains:
DE     RecName: Full=Glicentin;
DE   Contains:
DE     RecName: Full=Glicentin-related polypeptide;
DE              Short=GRPP;
DE   Contains:
DE     RecName: Full=Oxyntomodulin;
DE              Short=OXM;
DE              Short=OXY;
DE   Contains:
DE     RecName: Full=Glucagon;
DE   Contains:
DE     RecName: Full=Glucagon-like peptide 1;
DE              Short=GLP-1;
DE   Contains:
DE     RecName: Full=Glucagon-like peptide 1(7-37);
DE              Short=GLP-1(7-37);
DE   Contains:
DE     RecName: Full=Glucagon-like peptide 1(7-36);
DE              Short=GLP-1(7-36);
DE   Contains:
DE     RecName: Full=Glucagon-like peptide 2;
DE              Short=GLP-2;
DE   Flags: Precursor;
GN   Name=Gcg;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6094539; DOI=10.1016/s0021-9258(18)89859-3;
RA   Heinrich G., Gros P., Habener J.F.;
RT   "Glucagon gene sequence. Four of six exons encode separate functional
RT   domains of rat pre-proglucagon.";
RL   J. Biol. Chem. 259:14082-14087(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6548696; DOI=10.1210/endo-115-6-2176;
RA   Heinrich G., Gros P., Lund P.K., Bentley R.C., Habener J.F.;
RT   "Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino
RT   acid sequences of the rat pancreatic complementary deoxyribonucleic acid.";
RL   Endocrinology 115:2176-2181(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3528148; DOI=10.1016/s0021-9258(18)67324-7;
RA   Mojsov S., Heinrich G., Wilson I.B., Ravazzola M., Orci L., Habener J.F.;
RT   "Preproglucagon gene expression in pancreas and intestine diversifies at
RT   the level of post-translational processing.";
RL   J. Biol. Chem. 261:11880-11889(1986).
RN   [4]
RP   PROTEIN SEQUENCE OF 53-89.
RX   PubMed=7937770; DOI=10.1073/pnas.91.20.9362;
RA   Collie N.L., Walsh J.H., Wong H.C., Shively J.E., Davis M.T., Lee T.D.,
RA   Reeve J.R. Jr.;
RT   "Purification and sequence of rat oxyntomodulin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:9362-9366(1994).
RN   [5]
RP   FUNCTION OF OXYNTOMODULIN.
RX   PubMed=11564680; DOI=10.1210/endo.142.10.8430;
RA   Dakin C.L., Gunn I., Small C.J., Edwards C.M., Hay D.L., Smith D.M.,
RA   Ghatei M.A., Bloom S.R.;
RT   "Oxyntomodulin inhibits food intake in the rat.";
RL   Endocrinology 142:4244-4250(2001).
RN   [6]
RP   PROTEOLYTIC PROCESSING BY PCSK1 AND PCSK2.
RX   PubMed=8721980; DOI=10.1210/mend.10.4.8721980;
RA   Dhanvantari S., Seidah N.G., Brubaker P.L.;
RT   "Role of prohormone convertases in the tissue-specific processing of
RT   proglucagon.";
RL   Mol. Endocrinol. 10:342-355(1996).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=1692320; DOI=10.1016/s0021-9258(19)39030-1;
RA   Mojsov S., Kopczynski M.G., Habener J.F.;
RT   "Both amidated and nonamidated forms of glucagon-like peptide I are
RT   synthesized in the rat intestine and the pancreas.";
RL   J. Biol. Chem. 265:8001-8008(1990).
RN   [8]
RP   REVIEW.
RX   PubMed=10605628; DOI=10.1210/edrv.20.6.0385;
RA   Kieffer T.J., Habener J.F.;
RT   "The glucagon-like peptides.";
RL   Endocr. Rev. 20:876-913(1999).
RN   [9]
RP   REVIEW.
RX   PubMed=10322410; DOI=10.1016/s1043-2760(98)00136-2;
RA   Drucker D.J.;
RT   "Glucagon-like peptide 2.";
RL   Trends Endocrinol. Metab. 10:153-156(1999).
RN   [10]
RP   REVIEW.
RX   PubMed=12626323; DOI=10.1152/ajpendo.00492.2002;
RA   Jiang G., Zhang B.B.;
RT   "Glucagon and regulation of glucose metabolism.";
RL   Am. J. Physiol. 284:E671-E678(2003).
RN   [11]
RP   REVIEW.
RX   PubMed=14719035; DOI=10.1139/y03-107;
RA   Brubaker P.L., Anini Y.;
RT   "Direct and indirect mechanisms regulating secretion of glucagon-like
RT   peptide-1 and glucagon-like peptide-2.";
RL   Can. J. Physiol. Pharmacol. 81:1005-1012(2003).
RN   [12]
RP   REVIEW.
RX   PubMed=12554744; DOI=10.1210/me.2002-0306;
RA   Drucker D.J.;
RT   "Glucagon-like peptides: regulators of cell proliferation, differentiation,
RT   and apoptosis.";
RL   Mol. Endocrinol. 17:161-171(2003).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-152, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: [Glucagon]: Plays a key role in glucose metabolism and
CC       homeostasis. Regulates blood glucose by increasing gluconeogenesis and
CC       decreasing glycolysis. A counterregulatory hormone of insulin, raises
CC       plasma glucose levels in response to insulin-induced hypoglycemia.
CC       Plays an important role in initiating and maintaining hyperglycemic
CC       conditions in diabetes. {ECO:0000305|PubMed:10605628,
CC       ECO:0000305|PubMed:12626323}.
CC   -!- FUNCTION: [Glucagon-like peptide 1]: Potent stimulator of glucose-
CC       dependent insulin release (Probable). Also stimulates insulin release
CC       in response to IL6 (By similarity). Plays important roles on gastric
CC       motility and the suppression of plasma glucagon levels. May be involved
CC       in the suppression of satiety and stimulation of glucose disposal in
CC       peripheral tissues, independent of the actions of insulin. Has growth-
CC       promoting activities on intestinal epithelium. May also regulate the
CC       hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH,
CC       oxytocin, and vasopressin secretion. Increases islet mass through
CC       stimulation of islet neogenesis and pancreatic beta cell proliferation.
CC       Inhibits beta cell apoptosis (Probable). {ECO:0000250|UniProtKB:P01275,
CC       ECO:0000305|PubMed:10605628, ECO:0000305|PubMed:12554744,
CC       ECO:0000305|PubMed:14719035}.
CC   -!- FUNCTION: [Glucagon-like peptide 2]: Stimulates intestinal growth and
CC       up-regulates villus height in the small intestine, concomitant with
CC       increased crypt cell proliferation and decreased enterocyte apoptosis.
CC       The gastrointestinal tract, from the stomach to the colon is the
CC       principal target for GLP-2 action. Plays a key role in nutrient
CC       homeostasis, enhancing nutrient assimilation through enhanced
CC       gastrointestinal function, as well as increasing nutrient disposal.
CC       Stimulates intestinal glucose transport and decreases mucosal
CC       permeability. {ECO:0000305|PubMed:10322410,
CC       ECO:0000305|PubMed:10605628, ECO:0000305|PubMed:12554744,
CC       ECO:0000305|PubMed:14719035}.
CC   -!- FUNCTION: [Glicentin]: May modulate gastric acid secretion and the
CC       gastro-pyloro-duodenal activity. May play an important role in
CC       intestinal mucosal growth in the early period of life.
CC       {ECO:0000305|PubMed:10605628, ECO:0000305|PubMed:12554744}.
CC   -!- FUNCTION: Oxyntomodulin significantly reduces food intake.
CC       {ECO:0000269|PubMed:11564680}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000250|UniProtKB:P01275}.
CC   -!- SUBCELLULAR LOCATION: [Glucagon-like peptide 1]: Secreted
CC       {ECO:0000250|UniProtKB:P01275}.
CC   -!- TISSUE SPECIFICITY: Glucagon is secreted in the A cells of the islets
CC       of Langerhans. GLP-1, GLP-2, oxyntomodulin and glicentin are secreted
CC       from enteroendocrine cells throughout the gastrointestinal tract.
CC       {ECO:0000269|PubMed:1692320}.
CC   -!- INDUCTION: Glucagon release is stimulated by hypoglycemia and inhibited
CC       by hyperglycemia, insulin, and somatostatin. GLP-1 and GLP-2 are
CC       induced in response to nutrient ingestion.
CC   -!- PTM: Proglucagon is post-translationally processed in a tissue-specific
CC       manner in pancreatic A cells and intestinal L cells. In pancreatic A
CC       cells, the major bioactive hormone is glucagon cleaved by PCSK2/PC2. In
CC       the intestinal L cells PCSK1/PC1 liberates GLP-1, GLP-2, glicentin and
CC       oxyntomodulin. GLP-1 is further N-terminally truncated by post-
CC       translational processing in the intestinal L cells resulting in GLP-
CC       1(7-37) GLP-1-(7-36)amide. The C-terminal amidation is neither
CC       important for the metabolism of GLP-1 nor for its effects on the
CC       endocrine pancreas. {ECO:0000269|PubMed:8721980}.
CC   -!- SIMILARITY: Belongs to the glucagon family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; K02813; AAA41235.1; -; Genomic_DNA.
DR   EMBL; K02809; AAA41235.1; JOINED; Genomic_DNA.
DR   EMBL; K02810; AAA41235.1; JOINED; Genomic_DNA.
DR   EMBL; K02811; AAA41235.1; JOINED; Genomic_DNA.
DR   EMBL; K02812; AAA41235.1; JOINED; Genomic_DNA.
DR   PIR; A22655; GCRT.
DR   AlphaFoldDB; P06883; -.
DR   BMRB; P06883; -.
DR   STRING; 10116.ENSRNOP00000007356; -.
DR   iPTMnet; P06883; -.
DR   PhosphoSitePlus; P06883; -.
DR   PaxDb; 10116-ENSRNOP00000007356; -.
DR   UCSC; RGD:2668; rat.
DR   AGR; RGD:2668; -.
DR   RGD; 2668; Gcg.
DR   eggNOG; ENOG502RYPR; Eukaryota.
DR   InParanoid; P06883; -.
DR   PhylomeDB; P06883; -.
DR   Reactome; R-RNO-163359; Glucagon signaling in metabolic regulation.
DR   Reactome; R-RNO-381676; Glucagon-like Peptide-1 (GLP1) regulates insulin secretion.
DR   Reactome; R-RNO-381771; Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1).
DR   Reactome; R-RNO-416476; G alpha (q) signalling events.
DR   Reactome; R-RNO-420092; Glucagon-type ligand receptors.
DR   Reactome; R-RNO-422085; Synthesis, secretion, and deacylation of Ghrelin.
DR   PRO; PR:P06883; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0031769; F:glucagon receptor binding; IDA:RGD.
DR   GO; GO:0005179; F:hormone activity; IDA:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0048018; F:receptor ligand activity; ISO:RGD.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; ISO:RGD.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IDA:RGD.
DR   GO; GO:0071377; P:cellular response to glucagon stimulus; ISO:RGD.
DR   GO; GO:0006094; P:gluconeogenesis; ISO:RGD.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISO:RGD.
DR   GO; GO:0032099; P:negative regulation of appetite; IMP:RGD.
DR   GO; GO:1900118; P:negative regulation of execution phase of apoptosis; ISO:RGD.
DR   GO; GO:2001243; P:negative regulation of intrinsic apoptotic signaling pathway; ISO:RGD.
DR   GO; GO:0090280; P:positive regulation of calcium ion import; ISO:RGD.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISO:RGD.
DR   GO; GO:0045722; P:positive regulation of gluconeogenesis; ISO:RGD.
DR   GO; GO:0035774; P:positive regulation of insulin secretion involved in cellular response to glucose stimulus; ISO:RGD.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; ISO:RGD.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; ISO:RGD.
DR   GO; GO:0010737; P:protein kinase A signaling; ISO:RGD.
DR   GO; GO:0006109; P:regulation of carbohydrate metabolic process; TAS:RGD.
DR   GO; GO:0050796; P:regulation of insulin secretion; ISS:UniProtKB.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; TAS:RGD.
DR   GO; GO:0014823; P:response to activity; ISS:UniProtKB.
DR   GO; GO:1903576; P:response to L-arginine; IEP:RGD.
DR   Gene3D; 6.10.250.590; -; 3.
DR   InterPro; IPR015550; Glucagon.
DR   InterPro; IPR000532; Glucagon_GIP_secretin_VIP.
DR   PANTHER; PTHR11418; GLUCAGON; 1.
DR   PANTHER; PTHR11418:SF0; PRO-GLUCAGON; 1.
DR   Pfam; PF00123; Hormone_2; 3.
DR   PRINTS; PR00275; GLUCAGON.
DR   SMART; SM00070; GLUCA; 3.
DR   PROSITE; PS00260; GLUCAGON; 4.
PE   1: Evidence at protein level;
KW   Amidation; Cleavage on pair of basic residues; Direct protein sequencing;
KW   Hormone; Phosphoprotein; Reference proteome; Secreted; Signal.
FT   SIGNAL          1..20
FT   PEPTIDE         21..89
FT                   /note="Glicentin"
FT                   /evidence="ECO:0000250|UniProtKB:P01274"
FT                   /id="PRO_0000011303"
FT   PEPTIDE         21..50
FT                   /note="Glicentin-related polypeptide"
FT                   /evidence="ECO:0000250|UniProtKB:P09686"
FT                   /id="PRO_0000011304"
FT   PEPTIDE         53..89
FT                   /note="Oxyntomodulin"
FT                   /evidence="ECO:0000269|PubMed:7937770"
FT                   /id="PRO_0000011305"
FT   PEPTIDE         53..81
FT                   /note="Glucagon"
FT                   /evidence="ECO:0000250|UniProtKB:P01275"
FT                   /id="PRO_0000011306"
FT   PROPEP          84..89
FT                   /evidence="ECO:0000250|UniProtKB:P01275"
FT                   /id="PRO_0000011307"
FT   PEPTIDE         92..128
FT                   /note="Glucagon-like peptide 1"
FT                   /evidence="ECO:0000250|UniProtKB:P01275"
FT                   /id="PRO_0000011308"
FT   PEPTIDE         98..128
FT                   /note="Glucagon-like peptide 1(7-37)"
FT                   /evidence="ECO:0000250|UniProtKB:P01275"
FT                   /id="PRO_0000011309"
FT   PEPTIDE         98..127
FT                   /note="Glucagon-like peptide 1(7-36)"
FT                   /evidence="ECO:0000250|UniProtKB:P01275"
FT                   /id="PRO_0000011310"
FT   PROPEP          131..145
FT                   /evidence="ECO:0000250|UniProtKB:P15438"
FT                   /id="PRO_0000011311"
FT   PEPTIDE         146..178
FT                   /note="Glucagon-like peptide 2"
FT                   /evidence="ECO:0000250|UniProtKB:P15438"
FT                   /id="PRO_0000011312"
FT   REGION          23..59
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        23..42
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            52..53
FT                   /note="Cleavage; by PCSK2"
FT                   /evidence="ECO:0000250"
FT   SITE            83..84
FT                   /note="Cleavage; by PCSK1 and PCSK2"
FT                   /evidence="ECO:0000250"
FT   SITE            91..92
FT                   /note="Cleavage; by PCSK1"
FT                   /evidence="ECO:0000250"
FT   SITE            97..98
FT                   /note="Cleavage; by PCSK1"
FT                   /evidence="ECO:0000250"
FT   SITE            130..131
FT                   /note="Cleavage; by PCSK1"
FT                   /evidence="ECO:0000250"
FT   SITE            145..146
FT                   /note="Cleavage; by PCSK1"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         54
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P55095"
FT   MOD_RES         105
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P55095"
FT   MOD_RES         108
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P55095"
FT   MOD_RES         127
FT                   /note="Arginine amide"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         150
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P55095"
FT   MOD_RES         152
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
SQ   SEQUENCE   180 AA;  20846 MW;  76931409D03C7978 CRC64;
     MKTVYIVAGL FVMLVQGSWQ HAPQDTEENA RSFPASQTEP LEDPDQINED KRHSQGTFTS
     DYSKYLDSRR AQDFVQWLMN TKRNRNNIAK RHDEFERHAE GTFTSDVSSY LEGQAAKEFI
     AWLVKGRGRR DFPEEVAIAE ELGRRHADGS FSDEMNTILD NLATRDFINW LIQTKITDKK
//
